Abbott posted strong organic growth of 11% in Q4 when excluding Covid testing sales. This year the stock will hit a milestone: 400 consecutive quarterly dividend payments. But consistency doesn't come ...

Abbott is the name behind many well-known products.

A new automation system from Abbott, designed to improve workflows in clinical lab settings, has been granted FDA approval. The system, GLP systems Track, uses a self-propelled carrier system that ...

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive growth following a drop in Covid-test demand. The company reported 9% revenue ...

Sales at Abbott Laboratories' diagnostics unit dropped in the second quarter as demand for COVID-19 tests slumped. The company beat profit and sales estimates on strong sales of its medical devices.

ABT, is repositioning its business after ongoing challenges in its Nutrition segment. The company is advancing a major acquisition of Exact Sciences to expand into oncology diagnostics. Management is ...

Abbott Laboratories reported strong Q4 2023 earnings, with year-over-year growth in EPS and revenue. The company's 2024 guidance projects further growth and improved ...

Abbott Laboratories (NYSE:ABT) will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...